CLINICAL TRIAL: PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIB

临床试验：PX-171-001-蛋白酶体抑制剂剂量递增的 I 期研究

• 批准号: 7716842
• 负责人: PETER VOORHEES
• 金额: $ 0.42万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716842
• 关键词: Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Investigational Drugs; Learning; Phase I Clinical Trials; Purpose; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; multicatalytic endopeptidase complex; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to learn about the safety of an investigational drug called PR-171 at different dose levels.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是了解一种名为PR-171的研究药物在不同剂量水平下的安全性。